ReviewJournal of clinical pathology2013
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.
Review in Journal of clinical pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 6 syntheses or guidelines pooled it, 297 citations in OpenAlex.
- Quality and accuracy of radiomics models in predicting KRAS status in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.Targeted oncology · 2022Pooled it
- Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.Advances in therapy · 2019Guideline
- CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis.BMC medical imaging · 2017Pooled it
- Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.Clinical lung cancer · 2015Pooled it
- Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis.Targeted oncology · 2014Pooled it
- EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.British journal of cancer · 2017Trial
- Evaluation of Site-Specific Radioiodination of Anti-EGFR-Targeted DARPin E01 Using (4-Hydroxyphenyl)ethyl Maleimide.International journal of molecular sciences · 2026Article
- Review
- Global trends and research progress on immunotherapy forJournal of thoracic disease · 2026Article
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- AI-enabled molecular phenotyping and prognostic predictions in lung cancer through multimodal clinical information integration.Cell reports. Medicine · 2025Article
- ChatGPT in Oncology Diagnosis and Treatment: Applications, Legal and Ethical Challenges.Current oncology reports · 2025Review
- Current Biomarkers in Non-Small Cell Lung Cancer-The Molecular Pathologist's Perspective.Diagnostics (Basel, Switzerland) · 2025Review
- Unlocking the therapeutic potential of antibody-drug conjugates in targeting molecular biomarkers in non-small cell lung cancer.Journal of the Egyptian National Cancer Institute · 2025Review
- Anticancer drug response prediction integrating multi-omics pathway-based difference features and multiple deep learning techniques.PLoS computational biology · 2025Article
- RapidExtracellular vesicles and circulating nucleic acids · 2025Article
- The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study.Journal of the Egyptian National Cancer Institute · 2024Article
- Microfluidics-based EGFR mutation detection and its implication in the resource-limited clinical setting.International journal of experimental pathology · 2024Article
- Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence.Current oncology (Toronto, Ont.) · 2024Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsActivating mutations in the gene encoding epidermal growth factor receptor (EGFR) can confer sensitivity to EGFR tyrosine kinase inhibitors such as gefitinib in patients with advanced non-small-cell lung cancer. Testing for mutations in EGFR is therefore an important step in the treatment-decision pathway. We reviewed reported methods for EGFR mutation testing in patients with lung cancer, initially focusing on studies involving standard tumour tissue samples. We also evaluated data on the use of cytology samples in order to determine their suitability for EGFR mutation analysis.
methodsWe searched the MEDLINE database for studies reporting on EGFR mutation testing methods in patients with lung cancer.
resultsVarious methods have been investigated as potential alternatives to the historical standard for EGFR mutation testing, direct DNA sequencing. Many of these are targeted methods that specifically detect the most common EGFR mutations. The development of targeted mutation testing methods and commercially available test kits has enabled sensitive, rapid and robust analysis of clinical samples. The use of screening methods, subsequent to sample micro dissection, has also ensured that identification of more rare, uncommon mutations is now feasible. Cytology samples including fine needle aspirate and pleural effusion can be used successfully to determine EGFR mutation status provided that sensitive testing methods are employed.
conclusionsSeveral different testing methods offer a more sensitive alternative to direct sequencing for the detection of common EGFR mutations. Evidence published to date suggests cytology samples are viable alternatives for mutation testing when tumour tissue samples are not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.